

## References

### S-207

1. InterQual® Level of Care Criteria 2019. Acute Care Adult. McKesson Health Solutions, LLC.
2. Garderet L, Cook G, Auner HW, et al. Treatment options for relapse after autograft in multiple myeloma - report from an EBMT educational meeting. *Leuk Lymphoma*. 2017;58(4):797-808.
3. Autore F, Innocenti I, Luigetti M, et al. Autologous peripheral blood stem cell transplantation and the role of lenalidomide in patients affected by poems syndrome. *Hematol Oncol*. 2018;36(2):392-398.
4. Cook G, Iacobelli S, van Biezen A, et al. High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplantation. *Haemat*. 2017;102(1):160-167.
5. Maffini E, Storer BE, Sandmaier BM, et al. Long-term follow-up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma. *Haematol*
6. Cook G, Ashcroft AJ, Cairns DA, et al. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. *Lancet Haematol*. 2016;3(7):e340-351.
7. Ziogas DC, Terpos E, Dimopoulos MA. When to recommend a second autograft in patients with relapsed myeloma? *Leuk Lymphoma*. 2017;58(4):781-787.
8. McCarthy PL, Holstein SA. Role of stem cell transplant and maintenance therapy in plasma cell disorders. *Hematology Am Soc Hematol Educ Program*. 2016;2016(1):504-511.
9. Schneidawind C, Duerr-Stoerzer S, Faul C, et al. Follow-up of patients with refractory or relapsed multiple myeloma after allogeneic hematopoietic cell transplantation. *Clin Transplant*. 2017;31(7).
10. Marini C, Maia T, Bergantim R, et al. Real-life data on safety and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma. *Ann Hematol*. 2019;98(2):369-379.
11. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma. Version 7.2021.

12. Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. *Blood Cancer J*. 2020;10(9):94.
13. Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. *Am J Hematol*. 2020;95(5): 48-567.
14. Cavo M, Gay F, Beksac M, et al. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): A multicentre, randomised, open-label, phase 3 study. *Lancet Haematol*. 2020;7(6): e456-e468.
15. Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. *N Engl J Med*. 2017;376(14):1311-1320.
16. Mian H, Mian OS, Rochweg B, et al. Autologous stem cell transplant in older patients (age greater than or equal to 65) with newly diagnosed multiple myeloma: A systematic review and meta-analysis. *J Geriatr Oncol*. 2020;11(1):93-99.
17. Stadtmauer EA, Pasquini MC, Blackwell B, et al. Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: Results of the BMT CTN 0702 trial. *J Clin Oncol*. 2019;37(7):589-597.
18. Goldschmidt H, Baertsch MA, Schlenzka J, et al. Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: The randomized GMMG phase III trial ReLApsE. *Leukemia*. 2020.
19. Ikeda T, Mori K, Kawamura K, et al. Comparison between autologous and allogeneic stem cell transplantation as salvage therapy for multiple myeloma relapsing/progressing after autologous stem cell transplantation. *Hematol Oncol*. 2019;37(5):586-594.
20. Mikhael J, Ismaila N, Cheung MC, et al. Treatment of multiple myeloma: ASCO and CCO Joint Clinical Practice Guideline. *J Clin Oncol*. 2019;37